サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1370897

α1抗トリプシン欠乏症市場- 世界の産業規模、シェア、動向、機会、予測、2018～2028年、製品別、投与経路別、流通チャネル別、地域別、競合

Alpha-1 Antitrypsin Deficiency Disease Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Product, By Route Of Administration, By Distribution Channel, By Region, By Competition.

出版日
ページ情報
英文 173 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

α1抗トリプシン欠乏症市場- 世界の産業規模、シェア、動向、機会、予測、2018～2028年、製品別、投与経路別、流通チャネル別、地域別、競合
出版日: 2023年10月03日
発行: TechSci Research
ページ情報: 英文 173 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

α1抗トリプシン欠乏症の世界市場は、2022年に18億936万米ドルの評価額に達し、予測期間を通じて目覚ましい成長を遂げる構えで、2028年までの年間平均成長率（CAGR）は6.49%と予測され、2028年には26億2,718万米ドルに達する見込みです。

α1抗トリプシン欠乏症は、肺と肝臓に影響を及ぼす珍しい遺伝性疾患です。α1抗トリプシンタンパク質の量が不十分なために生じ、その結果、肺や肝臓の疾患に対する脆弱性が高くなります。稀な疾患であるにもかかわらず、α1抗トリプシン欠乏症は患者のQOLや医療システムに大きな影響を与えます。研究が進み、認知が広まるにつれ、α1抗トリプシン欠乏症市場は変化しつつあり、課題と機会の両方を提示しています。

α1抗トリプシンは肝臓で産生されるタンパク質で、酵素による炎症誘発性損傷から肺を守るために極めて重要です。α1抗トリプシン欠乏症の場合、遺伝子変異により、ミスフォールドしたタンパク質が血流に放出されずに肝臓に蓄積されます。この欠乏症は、慢性閉塞性肺疾患（COPD）のような肺疾患や肝硬変のような肝疾患への感受性を高める。

市場概要
予測期間 2024～2028年
2022年の市場規模 18億936万米ドル
2028年の市場規模 26億2,718万米ドル
CAGR 2023～2028年 6.49%
急成長セグメント α1プロテイナーゼ阻害剤
最大市場 北米

政府の取り組みと研究資金が世界のα1抗トリプシン欠損症市場を牽引α1抗トリプシン欠損症のような希少疾患の認知度が高まるにつれて、研究、診断、治療開発を支援する政策やプログラムが牽引役となっています。研究プロジェクト、臨床試験、患者支援のための資金が製薬会社や研究者を魅了し、加速度的な進歩に拍車をかけています。

主な市場促進要因

  • 1.患者数の増加：α1抗トリプシン欠乏症の世界市場は、患者数の増加により大きく成長しています。稀な遺伝性疾患ではあるが、認知度や診断精度が向上するにつれて、過少報告症例や誤診の結果、対象患者数が増加しています。症例の増加により、製薬や研究への関心が高まり、市場拡大の原動力となっています。
  • 2.規制当局の後押し：研究者、臨床医、患者、擁護団体、製薬企業の協力により、α1抗トリプシン欠乏症の理解、治療、患者ケアの進歩が促進されます。研究機関の枠を超えたコンソーシアム、製薬企業と大学との共同研究、デジタルデータの共有は、従来の研究や治療のアプローチを変革し、進歩を促進します。

主な市場課題

  • 1.過小診断と誤診：α1抗トリプシン欠乏症市場における大きな課題は、過小診断と誤診にあります。多くの患者が未診断のまま、あるいは他の肺疾患と誤診されたままであり、正確な治療戦略を遅らせています。
  • 2.認知度の低さ：α1抗トリプシン欠乏症は希少疾患であるため、一般市民や医療専門家の認知度が低く、診断の遅れや不十分なサポートの原因となっています。
  • 3.複雑な治療法：α1抗トリプシン欠乏症は、遺伝的性質と肺と肝臓の二重合併症のため、効果的な治療法の開発が複雑であり、両方の側面に対応する治療法が必要です。

主な市場動向

  • 1.技術の進歩：遺伝子スクリーニングの技術的進歩により、α1抗トリプシン欠乏症の早期発見が可能となり、積極的な介入が可能となります。プレシジョンメディシンは遺伝的体質に基づいて治療を調整し、有効性を高める。遺伝子治療と遺伝子編集は遺伝子の根源を治療することを探求し、疾病管理を一変させる可能性があります。
  • 2.共同研究：学際的な共同研究は、α1抗トリプシン欠乏症の理解と管理を加速させる。研究コンソーシアム、製薬企業と学術機関のパートナーシップ、患者支援団体が研究、技術革新、治療開発を促進します。

セグメント別洞察

  • 1.製品2022年、α1プロテイナーゼ阻害薬セグメントはα1抗トリプシン欠乏症市場を牽引し、今後も成長軌道を維持すると予想されます。酵素補充療法（ERT）により不足したA1PIレベルを補充することで、症状を緩和し、肺障害の進行を遅らせることができます。
  • 2.流通チャネル：α1抗トリプシン欠乏症患者が必要とする、様々な分野の専門家が関与する包括的なケアにより、2022年には病院薬局が市場を独占しています。

地域別洞察

北米：研究の中心地である北米は、主要機関、研究センター、製薬会社を擁し、α1抗トリプシン欠乏症の理解、診断、治療を推進しています。臨床試験は主にこの地域で行われ、新しい治療法への早期アクセスを可能にし、北米市場のリーダーシップを確固たるものにしています。この地域の可処分所得、医療支出、保険適用範囲が市場の優位性を高めています。

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 α1抗トリプシン欠損症の世界市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • 製品別（α1プロテイナーゼ阻害薬、気管支拡大薬、副腎皮質ホルモン、酸素療法）
    • 投与経路別（注射、経口、吸入）
    • 流通チャネル別（病院薬局、小売薬局、オンライン薬局）
    • 地域別
    • 企業別（主要企業5社のシェア）
  • 市場マップ
    • 製品別
    • 投与経路別
    • 流通チャネル別
    • 地域別

第6章 北米のα1抗トリプシン欠乏症市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • 製品別
    • 投与経路別
    • 流通チャネル別
    • 国別

第7章 欧州のα1抗トリプシン欠乏症市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • 製品別
    • 投与経路別
    • 流通チャネル別
    • 国別

第8章 アジア太平洋のα1抗トリプシン欠乏症市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • 製品別
    • 投与経路別
    • 流通チャネル別
    • 国別

第9章 南米のα1抗トリプシン欠乏症市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • タイプ別
    • 投与経路別
    • 流通チャネル別
    • 国別

第10章 中東・アフリカのα1抗トリプシン欠乏症市場展望

  • 市場規模および予測
    • 金額別
  • 市場シェアと予測
    • タイプ別
    • 投与経路別
    • 流通チャネル別
    • 国別

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 最近の展開
  • 合併・買収
  • 製品発表

第13章 競合情勢

  • Shire plc
  • GlaxoSmithKline plc
  • CSL Behring
  • AstraZeneca Plc.
  • Grifols S.A.
  • Teva Pharmaceutical Industries
  • Boehringer Ingelheim International GmbH
  • Kamada Pharmaceuticals
  • Pfizer Inc.
  • Baxter International Inc.

第14章 戦略的提言

第15章 調査会社について・免責事項

目次
Product Code: 15894

The Global Alpha-1 Antitrypsin Deficiency Disease Market reached a valuation of USD 1809.36 Million in 2022, and it is poised for impressive growth throughout the forecast period, with a projected Compound Annual Growth Rate (CAGR) of 6.49% up to 2028 and expected to reach USD 2627.18 Million by 2028. Alpha-1 Antitrypsin Deficiency (Alpha-1 Antitrypsin Deficiency Disease) is an uncommon genetic disorder impacting the lungs and liver. It arises due to insufficient levels of the alpha-1 antitrypsin protein, resulting in an elevated vulnerability to lung and liver diseases. Despite its rarity, Alpha-1 Antitrypsin Deficiency Disease significantly affects patients' quality of life and healthcare systems. As research advances and awareness spreads, the Alpha-1 Antitrypsin Deficiency Disease Market is undergoing changes, presenting both challenges and opportunities.

Alpha-1 antitrypsin is a liver-produced protein pivotal in safeguarding lungs against inflammation-induced damage from enzymes. In cases of Alpha-1 Antitrypsin Deficiency Disease, a genetic mutation leads to misfolded protein accumulation in the liver instead of release into the bloodstream. This deficiency heightens susceptibility to lung ailments like chronic obstructive pulmonary disease (COPD) and liver conditions such as cirrhosis.

While the Alpha-1 Antitrypsin Deficiency Disease market is relatively compact due to the disease's rarity, it garners attention from researchers, pharmaceutical firms, and healthcare providers. Notable players in diagnostics, treatments, and therapies concentrate on addressing the underlying deficiency and managing linked complications. Biotechnology, genomics, and personalized medicine progress yield targeted, effective treatments for Alpha-1 Antitrypsin Deficiency Disease, potentially revolutionizing patient outcomes.

Market Overview
Forecast Period2024-2028
Market Size 2022USD 1809.36 Million
Market Size 2028USD 2627.18 Million
CAGR 2023-20286.49%
Fastest Growing SegmentAlpha-1 Proteinase Inhibitor
Largest MarketNorth America

Government initiatives and research funding propel the global Alpha-1 Antitrypsin Deficiency Disease market. As rare disease awareness, like Alpha-1 Antitrypsin Deficiency Disease, heightens, policies and programs supporting research, diagnosis, and treatment development gain traction. Funds for research projects, clinical trials, and patient support captivate pharmaceutical companies and researchers, spurring accelerated advancements.

Primary Market Drivers

  • 1. Increasing Patient Base: The Global Alpha-1 Antitrypsin Deficiency Disease Market witnesses substantial growth due to a rising patient population. Though a rare genetic disorder, underreported cases and misdiagnoses result in a larger target group as awareness and diagnostic precision improve. Heightened cases prompt increased pharmaceutical and research focus, driving market expansion.
  • 2. Regulatory Backing: Collaborative efforts among researchers, clinicians, patients, advocacy groups, and pharmaceutical firms catalyze advancements in Alpha-1 Antitrypsin Deficiency Disease understanding, treatment, and patient care. Cross-institutional consortia, pharmaceutical-academic collaborations, and digital data sharing transform traditional research and treatment approaches, fostering progress.

Key Market Challenges

  • 1. Underdiagnosis and Misdiagnosis: A substantial challenge in the Alpha-1 Antitrypsin Deficiency Disease market lies in its underdiagnosis and misdiagnosis. Many patients remain undiagnosed or misdiagnosed as other lung conditions, delaying accurate treatment strategies.
  • 2. Limited Awareness: The rarity of Alpha-1 Antitrypsin Deficiency Disease results in limited awareness among the public and healthcare professionals, causing delayed diagnosis and insufficient support.
  • 3. Complex Treatment: Developing effective treatments for Alpha-1 Antitrypsin Deficiency Disease is intricate due to its genetic nature and dual lung-liver complications, necessitating therapies addressing both aspects.

Key Market Trends

  • 1. Technological Advancements: Technological breakthroughs in genetic screening enable early Alpha-1 Antitrypsin Deficiency Disease detection, allowing proactive intervention. Precision medicine tailors treatment based on genetic makeup, enhancing efficacy. Gene therapies and editing explore treating the genetic root, potentially transforming disease management.
  • 2. Collaborative Efforts: Cross-disciplinary collaborations accelerate Alpha-1 Antitrypsin Deficiency Disease understanding and management. Research consortia, pharmaceutical-academic partnerships, and patient advocacy groups expedite research, innovation, and treatment development.

Segment Insights

  • 1. Product: In 2022, the Alpha-1 Proteinase Inhibitor segment led the Alpha-1 Antitrypsin Deficiency Disease market and is expected to continue its growth trajectory. Replenishing deficient A1PI levels through enzyme replacement therapy (ERT) helps alleviate symptoms, slowing lung damage progression.
  • 2. Distribution Channel: In 2022, Hospital pharmacies dominated the market, driven by the comprehensive care Alpha-1 Antitrypsin Deficiency Disease patients require, involving specialists from various disciplines.

Regional Insights

North America: This research hub boasts leading institutions, research centers, and pharmaceutical companies, propelling Alpha-1 Antitrypsin Deficiency Disease understanding, diagnostics, and treatments. Clinical trials predominantly occur here, giving early access to new therapies and consolidating North America's market leadership. The region's disposable income, healthcare spending, and coverage bolster market dominance.

Key Market Players

  • Shire plc
  • GlaxoSmithKline plc
  • CSL Behring
  • AstraZeneca Plc.
  • Grifols S.A.
  • Teva Pharmaceutical Industries
  • Boehringer Ingelheim International GmbH
  • Kamada Pharmaceuticals
  • Pfizer Inc.
  • Baxter International Inc.

Report Scope:

  • In this report, the Global Alpha-1 Antitrypsin Deficiency Disease Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below.

Alpha-1 Antitrypsin Deficiency Disease Market, By Product:

  • Alpha-1 Proteinase Inhibitor
  • Bronchodilato
  • Corticosteroid
  • Oxygen Therapy

Alpha-1 Antitrypsin Deficiency Disease Market, By Route Of Administration:

  • Injection
  • Oral
  • Inhalation

Alpha-1 Antitrypsin Deficiency Disease Market, By Distribution Channel:

  • Hospitals Pharmacy
  • Retail Pharmacies
  • Online Pharmacies

Alpha-1 Antitrypsin Deficiency Disease Market, By Region:

  • North America
  • Asia-Pacific
  • Europe
  • Middle East & Africa
  • South America

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Alpha-1 Antitrypsin Deficiency Disease Market.

Available Customizations:

  • Global Alpha-1 Antitrypsin Deficiency Disease Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Alpha-1 Antitrypsin Deficiency Disease Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Alpha-1 Proteinase Inhibitor, Bronchodilators, Corticosteroids, Oxygen Therapy)
    • 5.2.2. By Route Of Administration (Injection, Oral, Inhalation)
    • 5.2.3. By Distribution Channel (Hospitals Pharmacy, Retail Pharmacies, Online Pharmacies)
    • 5.2.4. By Region
    • 5.2.5. By Company (Shares of Top 5 Market Players)
  • 5.3. Market Map
    • 5.3.1. By Product
    • 5.3.2. By Route of Administration
    • 5.3.3. By Distribution Channel
    • 5.3.4. By Region

6. North America Alpha-1 Antitrypsin Deficiency Disease Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Route of Administration
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
      • 6.2.4.1. United States Alpha-1 Antitrypsin Deficiency Disease Market Outlook
        • 6.2.4.1.1. Market Size & Forecast
        • 6.2.4.1.1.1. By Value
        • 6.2.4.1.2. Market Share & Forecast
        • 6.2.4.1.2.1. By Product
        • 6.2.4.1.2.2. By Route of Administration
        • 6.2.4.1.2.3. By Distribution Channel (
      • 6.2.4.2. Canada Alpha-1 Antitrypsin Deficiency Disease Market Outlook
        • 6.2.4.2.1. Market Size & Forecast
        • 6.2.4.2.1.1. By Value
        • 6.2.4.2.2. Market Share & Forecast
        • 6.2.4.2.2.1. By Product
        • 6.2.4.2.2.2. By Route of Administration
        • 6.2.4.2.2.3. By Distribution Channel
      • 6.2.4.3. Mexico Alpha-1 Antitrypsin Deficiency Disease Market Outlook
        • 6.2.4.3.1. Market Size & Forecast
        • 6.2.4.3.1.1. By Value
        • 6.2.4.3.2. Market Share & Forecast
        • 6.2.4.3.2.1. By Test
        • 6.2.4.3.2.2. By Route of Administration
        • 6.2.4.3.2.3. By Distribution Channel

7. Europe Alpha-1 Antitrypsin Deficiency Disease Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Route of Administration
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
      • 7.2.4.1. France Alpha-1 Antitrypsin Deficiency Disease Market Outlook
        • 7.2.4.1.1. Market Size & Forecast
        • 7.2.4.1.1.1. By Value
        • 7.2.4.1.2. Market Share & Forecast
        • 7.2.4.1.2.1. By Product
        • 7.2.4.1.2.2. By Route of Administration
        • 7.2.4.1.2.3. By Distribution Channel
      • 7.2.4.2. Germany Alpha-1 Antitrypsin Deficiency Disease Market Outlook
        • 7.2.4.2.1. Market Size & Forecast
        • 7.2.4.2.1.1. By Value
        • 7.2.4.2.2. Market Share & Forecast
        • 7.2.4.2.2.1. By Product
        • 7.2.4.2.2.2. By Route of Administration
        • 7.2.4.2.2.3. By Distribution Channel
      • 7.2.4.3. United Kingdom Alpha-1 Antitrypsin Deficiency Disease Market Outlook
        • 7.2.4.3.1. Market Size & Forecast
        • 7.2.4.3.1.1. By Value
        • 7.2.4.3.2. Market Share & Forecast
        • 7.2.4.3.2.1. By Product
        • 7.2.4.3.2.2. By Route of Administration
        • 7.2.4.3.2.3. By Distribution Channel
      • 7.2.4.4. Italy Alpha-1 Antitrypsin Deficiency Disease Market Outlook
        • 7.2.4.4.1. Market Size & Forecast
        • 7.2.4.4.1.1. By Value
        • 7.2.4.4.2. Market Share & Forecast
        • 7.2.4.4.2.1. By Product
        • 7.2.4.4.2.2. By Route of Administration
        • 7.2.4.4.2.3. By Distribution Channel
      • 7.2.4.5. Spain Alpha-1 Antitrypsin Deficiency Disease Market Outlook
        • 7.2.4.5.1. Market Size & Forecast
        • 7.2.4.5.1.1. By Value
        • 7.2.4.5.2. Market Share & Forecast
        • 7.2.4.5.2.1. By Product
        • 7.2.4.5.2.2. By Route of Administration
        • 7.2.4.5.2.3. By Distribution Channel

8. Asia Pacific Alpha-1 Antitrypsin Deficiency Disease Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Route of Administration
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
      • 8.2.4.1. China Alpha-1 Antitrypsin Deficiency Disease Market Outlook
        • 8.2.4.1.1. Market Size & Forecast
        • 8.2.4.1.1.1. By Value
        • 8.2.4.1.2. Market Share & Forecast
        • 8.2.4.1.2.1. By Product
        • 8.2.4.1.2.2. By Route of Administration
        • 8.2.4.1.2.3. By Distribution Channel
      • 8.2.4.2. India Alpha-1 Antitrypsin Deficiency Disease Market Outlook
        • 8.2.4.2.1. Market Size & Forecast
        • 8.2.4.2.1.1. By Value
        • 8.2.4.2.2. Market Share & Forecast
        • 8.2.4.2.2.1. By Product
        • 8.2.4.2.2.2. By Route of Administration
        • 8.2.4.2.2.3. By Distribution Channel
      • 8.2.4.3. South Korea Alpha-1 Antitrypsin Deficiency Disease Market Outlook
        • 8.2.4.3.1. Market Size & Forecast
        • 8.2.4.3.1.1. By Value
        • 8.2.4.3.2. Market Share & Forecast
        • 8.2.4.3.2.1. By Product
        • 8.2.4.3.2.2. By Route of Administration
        • 8.2.4.3.2.3. By Distribution Channel
      • 8.2.4.4. Japan Alpha-1 Antitrypsin Deficiency Disease Market Outlook
        • 8.2.4.4.1. Market Size & Forecast
        • 8.2.4.4.1.1. By Value
        • 8.2.4.4.2. Market Share & Forecast
        • 8.2.4.4.2.1. By Product
        • 8.2.4.4.2.2. By Route of Administration
        • 8.2.4.4.2.3. By Distribution Channel
      • 8.2.4.5. Australia Alpha-1 Antitrypsin Deficiency Disease Market Outlook
        • 8.2.4.5.1. Market Size & Forecast
        • 8.2.4.5.1.1. By Value
        • 8.2.4.5.2. Market Share & Forecast
        • 8.2.4.5.2.1. By Product
        • 8.2.4.5.2.2. By Route of Administration
        • 8.2.4.5.2.3. By Distribution Channel

9. South America Alpha-1 Antitrypsin Deficiency Disease Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Route of Administration
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
      • 9.2.4.1. Brazil Alpha-1 Antitrypsin Deficiency Disease Market Outlook
        • 9.2.4.1.1. Market Size & Forecast
        • 9.2.4.1.1.1. By Value
        • 9.2.4.1.2. Market Share & Forecast
        • 9.2.4.1.2.1. By Product
        • 9.2.4.1.2.2. By Route of Administration
        • 9.2.4.1.2.3. By Distribution Channel
      • 9.2.4.2. Argentina Alpha-1 Antitrypsin Deficiency Disease Market Outlook
        • 9.2.4.2.1. Market Size & Forecast
        • 9.2.4.2.1.1. By Value
        • 9.2.4.2.2. Market Share & Forecast
        • 9.2.4.2.2.1. By Product
        • 9.2.4.2.2.2. By Route of Administration
        • 9.2.4.2.2.3. By Distribution Channel
      • 9.2.4.3. Colombia Alpha-1 Antitrypsin Deficiency Disease Market Outlook
        • 9.2.4.3.1. Market Size & Forecast
        • 9.2.4.3.1.1. By Value
        • 9.2.4.3.2. Market Share & Forecast
        • 9.2.4.3.2.1. By Product
        • 9.2.4.3.2.2. By Route of Administration
        • 9.2.4.3.2.3. By Distribution Channel

10. Middle East & Africa Alpha-1 Antitrypsin Deficiency Disease Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Route of Administration
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
      • 10.2.4.1. South Africa Alpha-1 Antitrypsin Deficiency Disease Market Outlook
        • 10.2.4.1.1. Market Size & Forecast
        • 10.2.4.1.1.1. By Value
        • 10.2.4.1.2. Market Share & Forecast
        • 10.2.4.1.2.1. By Product
        • 10.2.4.1.2.2. By Route of Administration
        • 10.2.4.1.2.3. By Distribution Channel
      • 10.2.4.2. Saudi Arabia Alpha-1 Antitrypsin Deficiency Disease Market Outlook
        • 10.2.4.2.1. Market Size & Forecast
        • 10.2.4.2.1.1. By Value
        • 10.2.4.2.2. Market Share & Forecast
        • 10.2.4.2.2.1. By Product
        • 10.2.4.2.2.2. By Route of Administration
        • 10.2.4.2.2.3. By Distribution Channel
      • 10.2.4.3. UAE Alpha-1 Antitrypsin Deficiency Disease Market Outlook
        • 10.2.4.3.1. Market Size & Forecast
        • 10.2.4.3.1.1. By Value
        • 10.2.4.3.2. Market Share & Forecast
        • 10.2.4.3.2.1. By Product
        • 10.2.4.3.2.2. By Route of Administration
        • 10.2.4.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Competitive Landscape

  • 13.1. Shire plc
  • 13.2. GlaxoSmithKline plc
  • 13.3. CSL Behring
  • 13.4. AstraZeneca Plc.
  • 13.5. Grifols S.A.
  • 13.6. Teva Pharmaceutical Industries
  • 13.7. Boehringer Ingelheim International GmbH
  • 13.8. Kamada Pharmaceuticals
  • 13.9. Pfizer Inc.
  • 13.10. Baxter International Inc.

14. Strategic Recommendations

15. About us & Disclaimer